Tebipenem pivoxil
Chemical compound
From Wikipedia, the free encyclopedia
Tebipenem pivoxil, sold under the brand name Orapenem among others, is a beta-lactam antibiotic medication used for the treatment of complicated urinary tract infections, including pyelonephritis.[1] It is a broad-spectrum orally-administered antibiotic, from the carbapenem subgroup of beta-lactam antibiotics.[1] It was developed as a novel drug to combat bacteria that had acquired antibiotic resistance to commonly used antibiotics.[2][3] Tebipenem is the first carbapenem whose prodrug form is orally available.[4]
| |
 Tebipenem pivoxil | |
| Clinical data | |
|---|---|
| Trade names | Orapenem, others |
| Other names | Tebipenem pivoxil hydrobromide (USAN US) |
| AHFS/Drugs.com | utebzi |
| License data | |
| Routes of administration | By mouth |
| Drug class | Beta-lactam antibiotic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H31N3O6S2 |
| Molar mass | 497.63 g·mol−1 |
| 3D model (JSmol) | |
| |
The most common side effects include diarrhea, headache, nausea, abdominal pain, increased liver enzymes, and Clostridioides difficile infection.[5]
Medical uses
Tebipenem pivoxil is indicated for the treatment of complicated urinary tract infections, including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, and Enterococcus faecalis in adults who have limited or no alternative oral treatment options.[1]
In Japan, tebipenem pivoxil is approved for the treatment of haemophilus infections and streptococcal infections.[6]
Side effects
The most common side effects include diarrhea, headache, nausea, abdominal pain, increased liver enzymes, and Clostridioides difficile infection.[5]
History
The efficacy of tebipenem pivoxil was evaluated in adults with cUTI, including pyelonephritis, in a global, randomized, double-blind, double-dummy, noninferiority trial (NCT06059846).[5] In this trial, 1,690 hospitalized participants were randomly assigned to receive tebipenem pivoxil 600 mg orally every 6 hours or imipenem-cilastatin 500 mg intravenously every 6 hours for 7 to 10 days.[5] A total of 929 participants were considered the “intent-to-treat” population.[5]
